Novo CEO Doustdar 'Very Optimistic' About CagriSema

Show Transcript
Bloomberg Nov 4 08:45 · 4531 Views

Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year," Doustdar says. He speaks on Bloomberg Television after the company boosted its forecast for the year once again, sparking optimism after the new Wegovy pill and the older shot Ozempic helped buoy earnings.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Transcript
  • 00:00 Assuming first of all that you get FDA approval,
  • 00:03 it seems that you will be launching a new obesity drug during the new year, Kagri Sema.
  • 00:08 How do you anticipate this going in terms of direct to consumer sales
  • 00:12 playing out with this medicine?
  • 00:15 We are
  • 00:16 first of all, thank you for having me.
  • 00:18 We are very optimistic about Kagri Sema.
  • 00:21 It's a wonderful drug that meets the patients
  • 00:24 where they are and, and we have shown a lot of good data for it
  • 00:27 more recently and
  • 00:29 and we are getting ready.
  • 00:30 Of course, we're
  • 00:31 hopeful that we will be able to get the timely approval from FDA at the
  • 00:35 end of this year and, and and launch it
  • 00:38 at the beginning of next year.
  • 00:39 But we are already in production mode and training our team and staff to go not just a traditional way, but through all the channels.
  • 00:46 And as you just mentioned,
  • 00:48 E Health channels, our own Nova Care pharmacy will be a
  • 00:52 key
  • 00:53 access point for patients getting access to this new drug, which is a combination of a GOP1 that you know, some magnetite
  • 01:00 and amylene and new biology and novel way of
  • 01:03 making sure that you can reduce weight and good quality.
  • 01:06 Weight loss
  • 01:08 is at the forefront of what we're about to do.
  • 01:11 Will you launch immediately to indirect to consumer and what will pricing look like, you know, indirect to consumer compared to the others?
  • 01:20 So the first question I can answer, yes, absolutely.
  • 01:24 The second question I would have to tell you to you have to wait and see.
  • 01:27 We will not reveal our price strategy right now.
  • 01:29 What we have seen of course that affordability is an important element
  • 01:33 for Americans and across the world.
  • 01:35 So we will take that very seriously and make sure that it's priced according to the value it provides, but also
  • 01:42 according to the patience and affordability that we see is present in US.